Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Asthma (14)
  • Basic immunology (1)
  • x Biologicals (18)
  • Biomarkers (7)
  • Dermatology (4)
  • Drug allergy (2)
  • ENT (3)
  • Environmental allergy and climate change (1)
  • Epidemiology (3)
  • Genomics and proteomics (1)
  • Immune deficiencies and autoimmunity (1)
  • Infections (1)
  • Occupational allergy (1)
  • Ocular allergy (1)
  • One Health (1)
  • Pediatrics (1)
Poster available until
  • Until platform closure (1)
Poster categories
  • Thematic Poster Session (18)
keywords
Session Reference
  • x L-TPS02 (9)
  • L-TPS07 (11)
  • L-TPS08 (1)
  • L-TPS09 (3)
  • L-TPS10 (1)
  • L-TPS19 (1)
  • L-TPS21 (1)
  • TPS06 (8)
  • TPS09 (2)
  • TPS17 (4)
  • TPS18 (9)
  • TPS29 (1)
  • TPS51 (1)
  • TPS52 (5)
  • TPS55 (10)
  • TPS56 (5)
  • TPS57 (1)
  • TPS63 (1)
  • x TPS67 (9)
  • TPS69 (2)
18 results
Thumbnail

D1.116 - Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis

Thumbnail

D1.117 - Combing dual biologics therapy for severe asthma : a series of ten cases

Thumbnail

D1.118 - The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience

Thumbnail

D1.119 - Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model

Thumbnail

D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment

Thumbnail

D1.124 - Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab

Thumbnail

D1.125 - Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos

Thumbnail

D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD

Thumbnail

D1.131 - TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)

Thumbnail

D3.364 - Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema

Thumbnail

D3.358 - The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings

Thumbnail

D3.359 - Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment

Thumbnail

D3.362 - Use and safety of canakinumab during pregnancy

Thumbnail

D3.363 - Vitamin D3 deficiency promotes epithelial-to-mesenchymal transition and thus favours pulmonary fibrosis development in the murine model of hypersensitivity pneumonitis

Thumbnail

D3.365 - The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis

Thumbnail

D3.366 - Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria

Thumbnail

D3.367 - Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed-methods study

Thumbnail

D3.368 - Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM